Outcomes of Molecular Characteristics in Chinese BAP1-Mutant Non-Small Cell Lung Cancer Patients

被引：0
|
作者：
Ke, H. [1 ]
Xu, C. [2 ]
Wang, W. [3 ]
Zhang, Q. [4 ]
Zhuang, W. [2 ]
Zhu, Y. [5 ]
Huang, Y. [2 ]
Chen, G. [4 ]
Fang, M. [3 ]
Lv, T. [6 ]
Song, Y. [6 ]
机构：
[1] Nantong Univ, Affiliated Hosp, Nantong, Peoples R China
[2] Fujian Canc Hosp, Fuzhou, Fujian, Peoples R China
[3] Zhejiang Canc Hosp, Chemotherapy, Hangzhou, Zhejiang, Peoples R China
[4] Fujian Canc Hosp, Pathol, Fuzhou, Fujian, Peoples R China
[5] Zhejiang Rongjun Hosp, Thorac Dis Ctr, Jiaxing, Peoples R China
[6] Jinling Hosp, Nanjing, Jiangsu, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
non-small-cell lung cancer; BAP1; mutation; prognosis;
D O I：
10.1016/j.jtho.2019.08.2098
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP1.03-17
引用
收藏
页码：S960 / S960
页数：1
相关论文
共 50 条
  • [41] Clinicopathologic Characteristics and Survival Outcome in Chinese Patients with Non-Small Cell Lung Cancer and HGF Mutations
    Xu, C.
    Wang, W.
    Zhang, Q.
    Zhuang, W.
    Zhu, Y.
    Huang, Y.
    Chen, G.
    Fang, M.
    Lv, T.
    Song, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S962 - S962
  • [42] Molecular Spectrum of Patients with MSH2 Mutations in Chinese Non-Small Cell Lung Cancer
    Wang, W.
    Xu, C.
    Zhang, Q.
    Zhuang, W.
    Zhu, Y.
    Chen, Y.
    Fang, M.
    Chen, G.
    Lv, T.
    Song, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S719 - S719
  • [43] Disparities in Non-Small Cell Lung Cancer Outcomes
    Yamani, F.
    Zhao, W.
    Monde, R-A
    Reis, I.
    Hu, J.
    Lally, B.
    [J]. MODERN PATHOLOGY, 2014, 27 : 499A - 499A
  • [44] HIGH EXPRESSION OF BAP1 IS BIOMARKER OF BETTER PROGNOSTIC IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS
    Zuo, Y.
    Shen, Z.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 427 - 427
  • [45] Disparities in Non-Small Cell Lung Cancer Outcomes
    Yamani, F.
    Zhao, W.
    Monde, R-A
    Reis, I.
    Hu, J.
    Lally, B.
    [J]. LABORATORY INVESTIGATION, 2014, 94 : 499A - 499A
  • [46] Clinicopathological and Molecular Characteristics of Non-Small Cell Lung Cancer with BRAF Mutation
    Wang, Yue
    Li, Yuan
    [J]. LABORATORY INVESTIGATION, 2024, 104 (03) : S1965 - S1967
  • [47] Molecular characteristics of HRAS mutated non-small cell lung cancer (NSCLC)
    Trabolsi, Asaad
    Rodriguez, Estelamari
    Kareff, Samuel Alexander
    Korn, Michael
    Xiu, Joanne
    Liu, Stephen
    Walker, Philip
    Ma, Patrick
    Mamdani, Hirva
    Nieva, Jorge
    Borghaei, Hossein
    Nabhan, Chadi
    Nagasaka, Misako
    Puri, Sonam
    Lopes, Gilberto
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [48] Clinicopathologic characteristics and immunotherapy outcomes in SMARCA4-mutant (mut) non-small cell lung cancer (NSCLC).
    Alessi, Joao Victor Machado
    Glass, Carolyn
    Ricciuti, Biagio
    Spurr, Liam F.
    Sholl, Lynette M.
    Awad, Mark M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer and BRAF mutation
    Ding, Xi
    Zhang, Zengli
    Jiang, Tao
    Li, Xuefei
    Zhao, Chao
    Su, Bo
    Zhou, Caicun
    [J]. CANCER MEDICINE, 2017, 6 (03): : 555 - 562
  • [50] DRIVER GENE ALTERATIONS IN CHINESE NON-SMALL CELL LUNG CANCER PATIENTS
    Wu, Y.
    An, S.
    Chen, Z.
    Su, J.
    Zhang, X.
    Zhong, W.
    Yang, J.
    Zhou, Q.
    Yang, X.
    Mok, T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S30 - S30
12345